Skip to main content Skip to section navigation Skip to footer
Investor Relations
Back to lenz-tx.com
LENZ Therapeutics, Inc. IR Home
  • Overview
  • News & Events
  • Company Info
  • Financial Results
  • Stock Data
  • SEC Filings
  • Governance
  • Back to lenz-tx.com

Press Releases

News & Events

News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
  • Media
Mar 07, 2023 8:00am EST

LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies

Oct 18, 2022 8:00am EDT

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia

Apr 13, 2022 7:00am EDT

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

Jun 17, 2021 8:00am EDT

LENZ Therapeutics Debuts With $47 Million Series A Financing

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
©2025 LENZ Therapeutics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences